An Invisible Threat: Mutation-Mediated Resistance to Triazole Drugs in Aspergillus
- Cau D. PhamAffiliated withMycotic Diseases Branch, Centers for Disease Control and Prevention
- , Shawn R. LockhartAffiliated withMycotic Diseases Branch, Centers for Disease Control and Prevention Email author
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Aspergillosis has emerged as an important contributor to infection-related morbidity and mortality in susceptible populations. This comes at a time when we are also seeing an increase in the vulnerable populations themselves. At the same time, some parts of the world are reporting an increased incidence of aspergillosis refractory to triazole therapy. Resistance to triazole drugs may have major implications for aspergillosis management since our antifungal armamentarium is limited. This review gives an overview of populations at risk of developing aspergillosis and highlights resistance mechanisms that may contribute to morbidity and mortality in these vulnerable populations.
KeywordsAspergillus Aspergillus fumigatus Triazole Cyp51a Voriconazole Itraconazole Posaconazole Resistance
- An Invisible Threat: Mutation-Mediated Resistance to Triazole Drugs in Aspergillus
Current Fungal Infection Reports
Volume 6, Issue 4 , pp 288-295
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Aspergillus fumigatus